152 related articles for article (PubMed ID: 37073116)
1. Long-term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals.
Su H; Haque M; Becker S; Edlund K; Duda J; Wang Q; Reißing J; Marschall HU; Candels LS; Mohamed M; Sjöland W; Liao L; Drexler SA; Strowig T; Rahnenführer J; Hengstler JG; Hatting M; Trautwein C
Liver Int; 2023 Aug; 43(8):1699-1713. PubMed ID: 37073116
[TBL] [Abstract][Full Text] [Related]
2. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
[TBL] [Abstract][Full Text] [Related]
3. Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
Volkert I; Fromme M; Schneider C; Candels L; Lindhauer C; Su H; Thorhauge K; Pons M; Mohamed MR; Schneider KM; Strnad P; Trautwein C
Hepatology; 2024 Apr; 79(4):898-911. PubMed ID: 37625151
[TBL] [Abstract][Full Text] [Related]
4. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
[TBL] [Abstract][Full Text] [Related]
5. Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice.
Kabbani M; Michailidis E; Steensels S; Fulmer CG; Luna JM; Le Pen J; Tardelli M; Razooky B; Ricardo-Lax I; Zou C; Zeck B; Stenzel AF; Quirk C; Foquet L; Ashbrook AW; Schneider WM; Belkaya S; Lalazar G; Liang Y; Pittman M; Devisscher L; Suemizu H; Theise ND; Chiriboga L; Cohen DE; Copenhaver R; Grompe M; Meuleman P; Ersoy BA; Rice CM; de Jong YP
Cell Rep; 2022 Sep; 40(11):111321. PubMed ID: 36103835
[TBL] [Abstract][Full Text] [Related]
6. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
Unalp-Arida A; Ruhl CE
Hepatology; 2020 Mar; 71(3):820-834. PubMed ID: 31705824
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
Banini BA; Kumar DP; Cazanave S; Seneshaw M; Mirshahi F; Santhekadur PK; Wang L; Guan HP; Oseini AM; Alonso C; Bedossa P; Koduru SV; Min HK; Sanyal AJ
Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
[TBL] [Abstract][Full Text] [Related]
8. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis.
Valenti L; Maggioni P; Piperno A; Rametta R; Pelucchi S; Mariani R; Dongiovanni P; Fracanzani AL; Fargion S
World J Gastroenterol; 2012 Jun; 18(22):2813-20. PubMed ID: 22719190
[TBL] [Abstract][Full Text] [Related]
9. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
[TBL] [Abstract][Full Text] [Related]
10. PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.
Chen Y; Yan X; Xu X; Yuan S; Xu F; Liang H
Endocrine; 2020 Dec; 70(3):517-525. PubMed ID: 32862405
[TBL] [Abstract][Full Text] [Related]
11. Clinically silent LINE 1 insertion in the PNPLA3 gene may impede genotyping of the p.I148M variant.
Leníček M; Šmíd V; Pajer P; Nazarova A; Dvořák K; Subhanová I; Brůha R; Vítek L
Sci Rep; 2021 Oct; 11(1):20924. PubMed ID: 34686753
[TBL] [Abstract][Full Text] [Related]
12. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
Park J; Zhao Y; Zhang F; Zhang S; Kwong AC; Zhang Y; Hoffmann HH; Bushweller L; Wu X; Ashbrook AW; Stefanovic B; Chen S; Branch AD; Mason CE; Jung JU; Rice CM; Wu X
J Hepatol; 2023 Jan; 78(1):45-56. PubMed ID: 36049612
[TBL] [Abstract][Full Text] [Related]
13. The PNPLA3 variant I148M reveals protective effects toward hepatocellular carcinoma in mice via restoration of omega-3 polyunsaturated fats.
Patsenker E; Thangapandi VR; Knittelfelder O; Palladini A; Hefti M; Beil-Wagner J; Rogler G; Buch T; Shevchenko A; Hampe J; Stickel F
J Nutr Biochem; 2022 Oct; 108():109081. PubMed ID: 35691594
[TBL] [Abstract][Full Text] [Related]
14. PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.
Boeckmans J; Gatzios A; Schattenberg JM; Koek GH; Rodrigues RM; Vanhaecke T
Liver Int; 2023 May; 43(5):975-988. PubMed ID: 36719059
[TBL] [Abstract][Full Text] [Related]
15. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation.
BasuRay S; Smagris E; Cohen JC; Hobbs HH
Hepatology; 2017 Oct; 66(4):1111-1124. PubMed ID: 28520213
[TBL] [Abstract][Full Text] [Related]
16. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
[TBL] [Abstract][Full Text] [Related]
17. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
Cherubini A; Ostadreza M; Jamialahmadi O; Pelusi S; Rrapaj E; Casirati E; Passignani G; Norouziesfahani M; Sinopoli E; Baselli G; Meda C; Dongiovanni P; Dondossola D; Youngson N; Tourna A; Chokshi S; Bugianesi E; ; Della Torre S; Prati D; Romeo S; Valenti L
Nat Med; 2023 Oct; 29(10):2643-2655. PubMed ID: 37749332
[TBL] [Abstract][Full Text] [Related]
18. Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
Murray JK; Long J; Liu L; Singh S; Pruitt D; Ollmann M; Swearingen E; Hardy M; Homann O; Wu B; Holder JR; Sham K; Herberich B; Lo MC; Dou H; Shkumatov A; Florio M; Rulifson IC
Nucleic Acid Ther; 2021 Oct; 31(5):324-340. PubMed ID: 34297902
[TBL] [Abstract][Full Text] [Related]
19. Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C.
De Nicola S; Dongiovanni P; Aghemo A; Cheroni C; D'Ambrosio R; Pedrazzini M; Marabita F; Donnici L; Maggioni M; Fargion S; Colombo M; De Francesco R; Valenti L
PLoS One; 2014; 9(8):e106022. PubMed ID: 25171251
[TBL] [Abstract][Full Text] [Related]
20. Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
Caon E; Martins M; Hodgetts H; Blanken L; Vilia MG; Levi A; Thanapirom K; Al-Akkad W; Abu-Hanna J; Baselli G; Hall AR; Luong TV; Taanman JW; Vacca M; Valenti L; Romeo S; Mazza G; Pinzani M; Rombouts K
J Hepatol; 2024 Jun; 80(6):941-956. PubMed ID: 38365182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
